Kevin Balthaser - 01 Mar 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Mar 2023
Net transactions value
-$23,579
Form type
4
Filing time
03 Mar 2023, 19:09:46 UTC
Previous filing
03 Feb 2023
Next filing
05 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +1,475 +211% 2,175 01 Mar 2023 Direct F1
transaction ACRS Common Stock Options Exercise +1,100 +51% 3,275 01 Mar 2023 Direct F1
transaction ACRS Common Stock Options Exercise +2,375 +73% 5,650 01 Mar 2023 Direct F1
transaction ACRS Common Stock Sale $12,289 -1,000 -18% $12.29 4,650 02 Mar 2023 Direct F2, F3
transaction ACRS Common Stock Options Exercise +1,500 +32% 6,150 02 Mar 2023 Direct F1
transaction ACRS Common Stock Sale $11,290 -894 -15% $12.63 5,256 03 Mar 2023 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -1,475 -100% $0.000000* 0 01 Mar 2023 Common Stock 1,475 Direct F1, F6
transaction ACRS Restricted Stock Units Options Exercise $0 -1,100 -33% $0.000000 2,200 01 Mar 2023 Common Stock 1,100 Direct F1, F7
transaction ACRS Restricted Stock Units Options Exercise $0 -2,375 -25% $0.000000 7,125 01 Mar 2023 Common Stock 2,375 Direct F1, F8
transaction ACRS Restricted Stock Units Options Exercise $0 -1,500 -50% $0.000000 1,500 02 Mar 2023 Common Stock 1,500 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.96 to $12.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
F5 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.47 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F7 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F8 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F9 The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.